HOT NEWS
Pfizer and Medivation Announce Results From Two Phase 3 Studies in Dimebon » Pfizer Inc. (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) announced results from two Phase 3 trial...
Nycomed on track in 2009 with strong growth in Key Products » Nycomed was on track in 2009, with strong growth in Key Products and most emerging markets. Pantopra...
Bayer Successful in a Difficult Environment » 2009 was operationally one of the strongest years for the Bayer Group. "We were successful in a diff...
Phase III study of Avastin in advanced stomach cancer did not meet primary endpo... » Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the topline results from a global phase III trial inves...
Sanofi Pasteur's A(H1N1) Vaccine HUMENZA®* Recommended by European Medicines Ag... » Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announc...
FY2009: Merck KGaA Revenues Rise by 2.1% to € 7.7 Billion » Merck KGaA announced that Group total revenues rose 2.1% in 2009 - meeting the guidance given earlie...
GSK receives positive opinions in Europe for Tyverb® and Votrient™ » GlaxoSmithKline (GSK) announced that the European Medicines Agency's Committee for Medicinal Product...
My child matters Supports Seven New Childhood Cancer Care Projects » On the International Childhood Cancer Day, the International Union Against Cancer (UICC) and sanofi-...
Abbott Completes Acquisition of Solvay Pharmaceuticals » Abbott (NYSE: ABT) today announced that it has completed its EUR 4.5 billion ($6.2 billion) acquisit...
Merck Receives European Approval for ELONVA® (corifollitropin alfa injection) » Merck & Co., Inc., which operates outside the U.S. and Canada as MSD, today announced the European C...
Sanofi-aventis
sanofi-aventisSanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT : SAN) and in New York (NYSE : SNY). For further information, please visit www.sanofi-aventis.com.

Sanofi-aventis RSS Channel
Filter     Display # 
# Article Title Hits
1 Sanofi Pasteur's A(H1N1) Vaccine HUMENZA®* Recommended by European Medicines Agency 335
2 My child matters Supports Seven New Childhood Cancer Care Projects 345
3 Multaq® Approved in the European Union for patients with atrial fibrillation 481
4 Panenza® and Humenza® Influenza A(H1N1) Vaccines Demonstrate Robust Immune Response After One Dose 2514
5 Multaq® (dronedarone) Recommended for Approval in the European Union 945
6 Sanofi Pasteur and Butantan Institute to Provide A(H1N1) Vaccine to Brazilian Government 710
7 5-year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus® Compared to NPH 655
8 Sanofi-aventis to strengthen Insulin Production Capacities 627
9 Update on Clopidogrel centralized applications in the European Union 548
10 Sanofi-aventis introduces sanofi-aventis TV "A window on our company" 602
11 Sanofi-aventis builds a New Vaccine Manufacturing Facility in France with an investment of 350 million euros 887
12 Sanofi-aventis invests €100 million in new facility in Mexico 882
13 INTANZA®/IDflu®, first intradermal influenza vaccine, approved in the European Union 894
14 New England Journal of Medicine publishes results from the landmark ATHENA trial 986
15 European Commission Clears Acquisition of Zentiva NV by sanofi-aventis 661
16 Sanofi-aventis and Novozymes announce a development and commercialization collaboration 603
 
Bookmark and Share

Banner